Collectively, these findings suggest that ALDH2 downregulation enhances the inflammatory phenotype and drives metabolic reprogramming through the MAPK/ERK signaling pathway, ultimately promoting tumor growth. The gene discussed is ALDH2; the disease is neoplasm.